Correlation to the chemosensitivity test and metallothionein immunostaining in head and neck squamous cell carcionoma

头颈部鳞状细胞癌化疗敏感性试验与金属硫蛋白免疫染色的相关性

• 批准号: 09672079
• 负责人: MURAMATSU Yasunori
• 金额: $ 1.86万
• 依托单位: Asahi University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1997
• 资助国家: 日本
• 起止时间: 1997 至 1999
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-09672079/
• 关键词: squamous cell carcinoma; head and neck lesion; metallothionein; chemosensitivity test; cisplatin; Immunohistochemistry; 感受性試験

The present study dealts with correlation to the chemosensitivity test and immunohistochemical scoring of metallothionein (MT) in a total 36 cased of squamous cell carcinoma in the oral cavity (n=23), pharynx (n=3), maxillary sinus (n=3), larynx (n=6) and esophagus (n=1). Mainly, chemosensitivity drug test were testing cisplatin (CDDP).Immunohistochemical evaluation of MT reaction in squamous cell carcinoma in the oral cavity has already been described including scoring of MT index that MT positive cell SCC localized either tumor cell or stromal cell. The study also notes correlation among CDDP sensitivity test and MT profiles and index including clinical outcom, pathological grading and chemotherapy with cisplatin or carboplatin and also radiation therapy. MT Immunoreactivity was expressed both tumor cell cytoplasm and nuclei, and showed heterogeneous localization In tuor epithelial cells and In the stroma. Histiocytic and fibrocytic cells in both peripheral and interstitial stromas were also not stained homegeneously.CDDP inhibition index (II) showed 50% or higher (n=17) that were sensitivity cases and 19 cases were less than 50% that were no sensitivity cases. MT positive cell index (PI), 14 cases were showed 15% or higher that were immunoreactivity cases and 22 cases were less than 15% that were no reactivity cases. In these, MT PI 15% or higher and CDDP II less than 50% were II cases, MTPI less than 15% and CDDP II 50% or higher were 14 cases. These finding suggest that correlation with CDDP drug sensitivity and MT immunoreactivity case were 25 of 36% cases (69.4%).

本文对36例口腔鳞癌（23例）、咽鳞癌（3例）、上颌窦鳞癌（3例）、喉鳞癌（6例）和食管鳞癌（1例）进行了化疗敏感性试验和金属硫蛋白（MT）免疫组化评分的相关性研究。化疗药物敏感性试验主要是顺铂（cisplatin，CDDP），免疫组化评价口腔鳞状细胞癌MT反应，包括MT指数评分，MT阳性细胞SCC定位于肿瘤细胞或间质细胞。本研究还注意到CDDP敏感性试验与MT谱和指标之间的相关性，包括临床结局、病理分级和顺铂或卡铂化疗以及放射治疗。MT免疫反应阳性表达于肿瘤细胞胞浆和胞核，并在肿瘤上皮细胞和间质中呈异质性定位。CDDP抑制指数（II）≥ 50%（n=17）为敏感病例，<50%（n= 19）为不敏感病例。MT阳性细胞指数（PI）14例≥ 15%为阳性，22例<15%为阴性。其中MTPI ≥ 15%、CDDP Ⅱ <50%为Ⅱ型，MTPI <15%、CDDP Ⅱ ≥ 50%为14例。结果表明，CDDP药物敏感性与MT免疫阳性率相关者占69.4%（25/36%）。

项目成果

Y.Muramatsu,Y.Hasegawa,et.al: "Metallothionein Immunoreactivity In Head and Neck Carcinomas;Special Reference to Clinical Behaviors and Chemotherapiec Responses"Anticancer Research. 20. 1-8 (2000)

Y.Muramatsu、Y.Hasekawa 等人：“头颈癌中的金属硫蛋白免疫反应性；临床行为和化疗反应的特别参考”抗癌研究。

Y.Muramatsu, A.Kamegai et al: "Metallothionein Immunoreactivity In Head and Neck Carcinomas ; Special Reference to Clinical Behaviors and Chemotherapiec Responses"Anticancer Research. 20. 1-8 (2000)

Y.Muramatsu、A.Kamegai 等人：“头颈癌中的金属硫蛋白免疫反应性；临床行为和化疗反应的特别参考”抗癌研究。

Y.Muramatsu, Y.Hasegawa,et al.: "Mmetallothionein Immunoreactivity In Head and Neck Carcinomas ; Special Reference to Clinical Behaviors and Chemotherapiec Responses."Anticancer Research. 20. 1-8 (2000)

Y.Muramatsu、Y.Hasekawa 等人：“头颈癌中的金属硫蛋白免疫反应性；临床行为和化疗反应的特别参考。”抗癌研究。

Muramatsu,A., Kamegai,et al.: "Histochemical characteristics of calcium binding S100 proteins and bone morphogenetic proteins in chondro-osseous tumors"Oncology Reports. 4. 849-853 (1997)

Muramatsu,A.、Kamegai 等人：“软骨骨肿瘤中钙结合 S100 蛋白和骨形态发生蛋白的组织化学特征”肿瘤学报告。

Y.Muramatsu, A.Kamegai,et al.: "Novel CaィイD12+ィエD1-binding S100 Proteins, Glial Fibrillary Acidic Protein and Tenascin In Chondro-osseous Tumors"Acta Histochemica Cytochemica. 30. 445-453 (1997)

Y.Muramatsu、A.Kamegai 等人：“软骨骨肿瘤中的新型 CaiD12+D1 结合 S100 蛋白、神经胶质纤维酸性蛋白和腱生蛋白”Acta Histochemica Cytochemica 30. 445-453 (1997)。